- Full Year 2024 Astellas Pharma Inc Earnings Presentation TranscriptApr 25, 2024
- Astellas Pharma Inc Sustainability Meeting TranscriptFeb 21, 2024
- Q3 2024 Astellas Pharma Inc Earnings Presentation TranscriptFeb 05, 2024
- Astellas Pharma Inc IZERVAY Briefing TranscriptNov 05, 2023
- Q2 2024 Astellas Pharma Inc Earnings Presentation TranscriptNov 01, 2023
- Q1 2024 Astellas Pharma Inc Earnings Presentation TranscriptAug 01, 2023
- Astellas Pharma Inc to Acquire IVERIC bio Inc M&A Presentation TranscriptMay 01, 2023
- Full Year 2023 Astellas Pharma Inc Earnings Presentation TranscriptApr 27, 2023
- Astellas Pharma Inc Corporate- wide Digital Transformation Driven by Analytics Briefing TranscriptMar 27, 2023
- Astellas Pharma Inc Sustainability Meeting TranscriptFeb 17, 2023
- Q3 2023 Astellas Pharma Inc Earnings Presentation TranscriptFeb 06, 2023
- Astellas Pharma Inc R&D Briefing TranscriptDec 09, 2022
- Q2 2023 Astellas Pharma Inc Earnings Presentation TranscriptOct 31, 2022
- Astellas Pharma Inc Fezolinetant Briefing TranscriptOct 17, 2022
- Q1 2023 Astellas Pharma Inc Earnings Presentation TranscriptAug 01, 2022
- Full Year 2022 Astellas Pharma Inc Earnings Presentation TranscriptApr 27, 2022
- Astellas Pharma Inc R&D Meeting TranscriptMar 09, 2022
- Astellas Pharma Inc Sustainability Briefing TranscriptFeb 28, 2022
- Q3 2022 Astellas Pharma Inc Earnings Presentation TranscriptFeb 02, 2022
- Astellas Pharma Inc R&D Meeting TranscriptDec 07, 2021
- Q2 2022 Astellas Pharma Inc Earnings Presentation TranscriptOct 29, 2021
- Q1 2022 Astellas Pharma Inc Earnings Call TranscriptJul 30, 2021€13.04 (-10.38%)Earnings
- Astellas Pharma Inc. Corporate Strategic Plan Presentation TranscriptMay 26, 2021
- Full Year 2021 Astellas Pharma Inc Earnings Call TranscriptApr 27, 2021€12.28 (-1.96%)Earnings
- Q3 2021 Astellas Pharma Inc Earnings Call TranscriptJan 29, 2021€13.4 (-1.58%)Earnings
- Astellas Pharma Inc R&D Meeting TranscriptDec 10, 2020
- Q2 2021 Astellas Pharma Inc Earnings Presentation TranscriptOct 30, 2020
- Q1 2021 Astellas Pharma Inc Earnings Call TranscriptAug 04, 2020€13.59 (-0.18%)Earnings
- Full Year 2020 Astellas Pharma Inc Earnings Call TranscriptMay 18, 2020€14.89 (+0.95%)Earnings
- Q3 2020 Astellas Pharma Inc Earnings Call TranscriptJan 31, 2020€16.05 (+2.26%)Earnings
- Astellas Pharma Inc Approaches to Immuno-Oncology R&D Conference Call TranscriptDec 10, 2019
- Astellas Pharma Inc Acquisition of Audentes Therapeutics Inc Call TranscriptDec 03, 2019
- Q2 2020 Astellas Pharma Inc Earnings Call TranscriptOct 31, 2019€15.29 (+1.06%)Earnings
- Astellas Pharma Inc Enfortumab Vedotin Call TranscriptOct 01, 2019
- Q1 2020 Astellas Pharma Inc Earnings Call TranscriptJul 30, 2019€12.34 (-0.80%)Earnings
- Full Year 2019 Astellas Pharma Inc Earnings Call TranscriptApr 25, 2019€11.9 (-0.75%)Earnings
Q3 2020 Astellas Pharma Inc Earnings Call Transcript
I'm the CSO and CFO, Naoki Okamura. Thank you very much for participating in the conference call by Astellas on the third quarter financial results for fiscal year 2019. Today, the time is limited. So initially, I'd like to spend about 20 minutes to give you an overview of the financial results and explain the initiatives for sustainable growth and capital allocation. And then we will entertain your questions later.
Page 2 is a cautionary statement regarding forward-looking information, which was already read, so please turn to Page 4. First of all, this is an overview of the third quarter financial results based on year-on-year comparisons. Revenue and core operating profit declined, but excluding ForEx impact, revenue and profit increased. So our business progressed favorably as expected, due to the LOE of Tarceva, VESIcare in the United States and Europe and Tarceva in the United States and termination of Symbicort and KM bioproducts in Japan, sales declined substantially.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)